Key Takes:· 交易破裂:高光缔约15个月后快速崩塌·事件脉络:从交易盛宴到法律深渊·争议核心:数据与合同欺诈的罗生门· 持续发酵:案件后续进展与法律博弈· 启示录:对中国药企出海BD协议的6条启示· 结语:中国资产如何不被“退回”引言:一场原本备受瞩目的13亿美元药物收购案,在短短一年后演变为一场涉及欺诈指控和8.3亿美元(约合60亿人民币)索赔的跨国法律纠纷,不仅揭示了生物医药领域 ...
Source LinkKey Takes:· 交易破裂:高光缔约15个月后快速崩塌·事件脉络:从交易盛宴到法律深渊·争议核心:数据与合同欺诈的罗生门· 持续发酵:案件后续进展与法律博弈· 启示录:对中国药企出海BD协议的6条启示· 结语:中国资产如何不被“退回”引言:一场原本备受瞩目的13亿美元药物收购案,在短短一年后演变为一场涉及欺诈指控和8.3亿美元(约合60亿人民币)索赔的跨国法律纠纷,不仅揭示了生物医药领域 ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.